Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/113749
Full metadata record
DC FieldValueLanguage
dc.contributor.authorParovincaka, Jekaterina-
dc.contributor.authorVella Szijj, Janis-
dc.contributor.authorSerracino-Inglott, Anthony-
dc.contributor.authorAzzopardi, Lilian M.-
dc.date.accessioned2023-10-10T12:46:55Z-
dc.date.available2023-10-10T12:46:55Z-
dc.date.issued2023-
dc.identifier.citationParovincaka, J., Szijj, J. V., Serracino-Inglott, A., & Azzopardi, L. M. (2023). Cannabis for medicinal use in patients with rare diseases. Translational Science of Rare Diseases, 6(4), 123-135.en_GB
dc.identifier.issn22146512-
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/113749-
dc.description.abstractPatients with Rare Diseases (RDs) present with chronic and debilitating symptoms such as pain, anxiety and epileptic seizures. Symptoms can be unresponsive to conventional treatment and may lead to a decreased Quality of Life for patients. Cannabinoids have been reported to be efficacious against chronic pain refractory to conventional analgesics, anxiety and seizures. OBJECTIVE: Identification of RDs for which Medicinal Cannabis (MC) can be used and identification of issues related to RDs and perceptions on the use of MC in patients with RDs. METHODS: Study was divided into 2 phases. Phase 1: Literature Review to identify RDs in which cannabis or cannabinoids are used Phase 2: Development, validation and dissemination of 2 questionnaires for: (i) Health Care Professionals (HCPs) and (ii) RD patients. RESULTS: Cannabinoids were described as possible therapeutic agents in 20 RDs. The questionnaires were completed by 101 HCPs and 38 RD patients. Thirty-three HCPs had no experience on use of MC but would consider using it in their practice for management of RDs. Most patients (n = 29) did not have experience with use of MC and 20 patients would consider using MC to treat their condition or relieve symptoms of their disease. CONCLUSION: The study helps identify the potential of MC use in RDs associated with chronic symptoms such as pain, muscle spasticity, seizures and anxiety.en_GB
dc.language.isoenen_GB
dc.publisherIOS Pressen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectRare diseasesen_GB
dc.subjectCannabis -- Therapeutic useen_GB
dc.subjectCannabis -- Health aspectsen_GB
dc.subjectTetrahydrocannabinolen_GB
dc.subjectCannabinoidsen_GB
dc.titleCannabis for medicinal use in patients with rare diseasesen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.3233/TRD-230060-
dc.publication.titleTranslational Science of Rare Diseasesen_GB
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
Cannabis_for_medicinal_use_in_patients_with_rare_diseases(2023).pdf282.71 kBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.